Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Optimization and characterization of expanded NKreg cells for therapy of chronic graft-versus-host disease
EF 2020-21
Résumé
Hematopoietic Stem Cell Transplantation (HSCT) is a critical immune-based therapeutic option for patients with high-risk and relapsed blood cancers. However, HSCT is attributed to an increased risk of complications, the most severe being chronic graft-versus-host-disease (cGvHD), in which foreign donor immune cells attack the recipient's tissues. cGvHD occurs in 25% of pediatric and 60% of adult HSCT survivors. It is known to cause chronic organ damage and has a 10-25% mortality rate. My team has identified a cGvHD biomarker (a non-cytolytic CD56bright Natural Killer population (NKreg)) closely correlated with an inhibition of cGvHD. Further, the adoptive transfer of expanded cytolytic NK cells has shown to potentially decrease leukemia relapse with no increase in GvHD. Thus, we hypothesize that the adoptive transfer of expanded NKreg cells after HSCT represents a significant strategy to decrease cGvHD without increasing leukemia relapse. To address my hypothesis, I will first determine the functional characteristics of CD56bright non-cytolytic NKreg cells associated with successful and failed suppression of cGvHD. Second, I will optimize and operationalize the expansion of functional NKreg cells. Third, I will evaluate the effect of expanded NKreg cells on cGvHD effector and suppressor immune populations in in vitro and in vivo models. In completion of my proposed research, I expect to understand the characteristics of human CD56bright NKreg cells that associate with no development of cGvHD and establish an optimal expansion protocol. These approaches will provide a biological understanding for developing strategies to augment NKreg cells as an adoptive transfer therapy for cGvHD, significantly contributing to the goal of improving the safety and efficacy of HSCT.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
449621
Name
Lauener Madeline
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Optimization and characterization of expanded NKreg cells for therapy of chronic graft-versus-host disease
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cd56 Bright Natural Killer Cells; Cell Therapy; Chronic Graft-Versus-Host Disease; Immune Regulation; Immunology; Regulatory Natural Killer Cells; Transplantation
Abstract
Hematopoietic Stem Cell Transplantation (HSCT) is a critical immune-based therapeutic option for patients with high-risk and relapsed blood cancers. However, HSCT is attributed to an increased risk of complications, the most severe being chronic graft-versus-host-disease (cGvHD), in which foreign donor immune cells attack the recipient's tissues. cGvHD occurs in 25% of pediatric and 60% of adult HSCT survivors. It is known to cause chronic organ damage and has a 10-25% mortality rate. My team has identified a cGvHD biomarker (a non-cytolytic CD56bright Natural Killer population (NKreg)) closely correlated with an inhibition of cGvHD. Further, the adoptive transfer of expanded cytolytic NK cells has shown to potentially decrease leukemia relapse with no increase in GvHD. Thus, we hypothesize that the adoptive transfer of expanded NKreg cells after HSCT represents a significant strategy to decrease cGvHD without increasing leukemia relapse. To address my hypothesis, I will first determine the functional characteristics of CD56bright non-cytolytic NKreg cells associated with successful and failed suppression of cGvHD. Second, I will optimize and operationalize the expansion of functional NKreg cells. Third, I will evaluate the effect of expanded NKreg cells on cGvHD effector and suppressor immune populations in in vitro and in vivo models. In completion of my proposed research, I expect to understand the characteristics of human CD56bright NKreg cells that associate with no development of cGvHD and establish an optimal expansion protocol. These approaches will provide a biological understanding for developing strategies to augment NKreg cells as an adoptive transfer therapy for cGvHD, significantly contributing to the goal of improving the safety and efficacy of HSCT.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lauener, Madeline
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~